Stocks
Amgen Stock Jumps 3.9% on Positive Dazodalibep Trial Results
Amgen Inc's stock (AMGN) rose by 3.90% on September 22, driven by positive results from its Phase 3 clinical trial for dazodalibep in adult patients with Sjögren's disease.
The study demonstrated statistically significant and clinically meaningful reductions in systemic disease activity compared to placebo over a 48-week evaluation period.
The successful late-stage readout positions dazodalibep as a potentially groundbreaking, first-in-class commercial opportunity for Amgen.
Investors are also reassessing the company's underlying pipeline and valuation, with renewed focus on its diverse late-stage portfolio, including the expanding Phase 3 MARITIME clinical program for MariTide.